- $1.66bn
- $1.37bn
- $184.42m
Stoke Therapeutics jumps on positive early-stage data for epilepsy drug
U.S. RESEARCH ROUNDUP-Altair Engineering, Applied Therapeutics, Microsoft
Stoke Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Stoke Therapeutics Announces Landmark New Data That Support The Potential For STK-001 to be the First Disease-Modifying Medicine
Stoke Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview
Brief: Stoke Therapeutics Anticipates Data In Q1 2024 From Studies Of STK-001 For Treatment Of Dravet Syndrome
Brief: Stoke Therapeutics - As Of Sept. 30 $214.7 Million In Cash, Cash Equivalents & Marketable Securities, To Fund Operations To End Of 2025
Brief: Stoke Therapeutics Q2 revenue USD -2.481 million
Stoke Therapeutics Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Stoke Therapeutics Announces New Safety & Efficacy Data For Stk-001 Studies
Stoke Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Stoke Therapeutics Q1 Basic Loss Per Share $0.53
Brief: Stoke Therapeutics Reports First Quarter Financial Results And Provides Business Updates
Brief: Stoke Therapeutics Announces That FDA Will Allow The Administration Of A Higher Single Dose Of Stk-001 (70Mg) In The Ongoing Phase 1/2A Monarch Study Of Children And Adolescents With Dravet Syndrome
Stoke Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Stoke Therapeutics Reports Fourth Quarter And 2022 Financial Results
Stoke Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Boeing, Motorola Solutions, Tractor Supply
Brief: Stoke Therapeutics Highlights Strategic Priorities And Anticipated Milestones For 2023